QSAM Biosciences EV/EBIT
Cos'è EV/EBIT di QSAM Biosciences?
EV/EBIT di QSAM Biosciences, Inc. è N/A
Qual è la definizione di EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT di aziende nel Health Care settore su OTC rispetto a QSAM Biosciences
Cosa fa QSAM Biosciences?
QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.
Aziende con ev/ebit simili a QSAM Biosciences
- Zacapa Resources Ltd ha EV/EBIT di N/A
- Dxi Capital Corp ha EV/EBIT di N/A
- African Gold ha EV/EBIT di N/A
- Contact Gold ha EV/EBIT di N/A
- CarParts.com Inc ha EV/EBIT di N/A
- Cel-Sci ha EV/EBIT di N/A
- QSAM Biosciences ha EV/EBIT di N/A
- Nephros ha EV/EBIT di N/A
- Nephros ha EV/EBIT di N/A
- Nephros ha EV/EBIT di N/A
- Nephros ha EV/EBIT di N/A
- Homerun Resources ha EV/EBIT di N/A
- DelMar Pharmaceuticals ha EV/EBIT di N/A